Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB122 + TAS-120 + cisplatin + gemcitabine
- Development stage
- Phase 3
- Lead developer
- Arcus Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AB122 + TAS-120 + cisplatin + gemcitabine is a multi-agent investigational combination therapy used in phase 1 clinical trials for advanced or metastatic adenocarcinoma or adenosquamous biliary tract cancer. AB122 is a fully human monoclonal antibody targeting programmed cell death-1 (PD-1), blocking immunosuppressive checkpoints and enhancing T-cell activation[3][7]. TAS-120 is a small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), disrupting oncogenic signaling in cancers with FGFR alterations[7]. Cisplatin is a platinum-based chemotherapeutic agent that induces apoptosis via DNA cross-linking, and gemcitabine is a nucleoside analog antimetabolite inhibiting DNA synthesis, both standard-of-care cytotoxics for various solid tumors[2][4][6]. This combination is under investigation to assess safety, tolerability, and efficacy by leveraging immune checkpoint inhibition, targeted therapy, and cytotoxic chemotherapy for advanced solid tumors[7].
- Other names
- AB122 + TAS-120 + cisplatin + gemcitabine
02
Targets
DNAFGFR (FGFR family)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on AB122 + TAS-120 + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB122 + TAS-120 + cisplatin + gemcitabine.